Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11174283-B2
Application number	US-202117205745-A
Country	US
Kind code	B2
Filing date	Mar 18, 2021
Priority date	Dec 6, 2019
Publication date	Nov 16, 2021
Grant date	Nov 16, 2021

Abstract

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

First claim

What is claimed is:

1. A method of producing aflibercept, comprising:
(a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM);
(b) binding aflibercept from said clarified harvest to a Protein A resin, wherein said aflibercept includes oxidized species of aflibercept that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
(c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said affinity eluate comprises oxidized species of aflibercept;
(d) subjecting said eluted aflibercept to anion exchange (AEX) chromatography column; and
(e) collecting a flowthrough fraction, wherein the percent of oxidized species of aflibercept in said affinity eluate is greater than the percent of oxidized species of aflibercept in said flowthrough fraction when the concentrations of protein in said affinity eluate and flowthrough fraction are normalized, and
wherein said oxidized species of aflibercept is measured by subjecting said affinity eluate and said flowthrough fraction to digestion, followed by their analysis using reverse-phase ultra-performance chromatography (UPLC), detection at wavelengths of 280 nm, 320 nm and 350 nm and mass spectrometry analysis using a first mobile phase of 0.1% v/v formic acid in water and a second mobile phase of 0.1% v/v formic acid in acetonitrile.

2. The method of claim 1 , wherein said oxidized amino acid residue is selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, and SEQ ID NO.: 67.

3. A method of producing aflibercept, comprising:
(a) producing clarified harvest of cells cultured in a chemically defined medium (CDM), wherein said clarified harvest comprises one or more aflibercept variants, wherein said variants have at least one oxidized amino acid residue selected from group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof, wherein a protein sample from said clarified harvest comprises aflibercept and at least one aflibercept variant, and wherein said protein sample has a b* value of more than 0.5 when the concentration of said protein sample is normalized to 10.0 g/L;
(b) binding aflibercept from said clarified harvest to a first capture chromatography;
(c) eluting said aflibercept of step (b) forming an eluate, wherein said eluate has a first color;
(d) subjecting said affinity eluate to an anion exchange chromatography (AEX) column; and
(e) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color is a more intense yellow-brown color than said second color when said eluate and said flowthrough fraction protein concentrations are normalized.

4. The method of claim 3 , wherein said first capture chromatography comprises Protein A resin.

5. The method of claim 3 , wherein said oxidized amino acid residue is histidine.

6. The method of claim 3 , wherein said oxidized amino acid residue is tryptophan.

7. The method of claim 3 , wherein said oxidized amino acid residue is selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 56, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 67, SEQ ID NO.: 68, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71, and combinations thereof.

8. The method of claim 3 , further comprising at least one additional chromatographic step selected from the group consisting of: cation exchange chromatography, hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

9. The method of claim 1 , wherein said oxidized amino acid residue is histidine.

10. The method of claim 1 , wherein said oxidized amino acid residue is tryptophan.

11. The method of claim 1 , wherein said cells are selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

12. The method of claim 1 further comprising at least one additional chromatographic step selected from the group consisting of: cation exchange chromatography (CEX), hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

Assignees

• Regeneron Pharma
• Regeneran Pharmaceuticals Inc

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha
• Wang Shunhai
• Li Ning

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title